BCNU (NSC-409962) in the treatment of advanced Hodgkin's disease, lymphosarcoma, and reticulum cell sarcoma.
D000328:Adult; D000368:Aged; D001855:Bone Marrow Diseases / Q000188:drug therapy; D001859:Bone Neoplasms / Q000188:drug therapy; D002330:Carmustine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004351:Drug Resistance; D005260:Female; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006402:Hematologic Diseases / Q000139:chemically induced; D006689:Hodgkin Disease / Q000188:drug therapy*; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D013997:Time Factors
D002330:Carmustine